Edition:
United Kingdom

People: Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

34.60USD
21 Nov 2018
Change (% chg)

$0.55 (+1.62%)
Prev Close
$34.05
Open
$34.31
Day's High
$35.03
Day's Low
$34.28
Volume
1,571,062
Avg. Vol
1,631,647
52-wk High
$39.43
52-wk Low
$24.54

Ballinger, Kevin 

Mr. Kevin J. Ballinger is Executive Vice President and Global President - Interventional Cardiology of the Company. In his current role, Mr. Ballinger is responsible for developing and bringing to market innovative solutions that diagnose and treat coronary artery disease and structural heart disorders. Prior to that, he served as senior vice president from January 2013 to February 2017. Mr. Ballinger has more than 20 years of interventional cardiology experience. Prior to his current role, he was also president, interventional cardiology and held a variety of engineering and general management positions within our Interventional Cardiology and Peripheral Interventions business units, including vice president and general manager, group program management, cardiology, rhythm and vascular; vice president of research and development, peripheral interventions and vice president of program management, cardiovascular. Mr. Ballinger earned a B.S. in mechanical engineering from Michigan Technological University and an M.B.A. from the University of Minnesota.

Basic Compensation

Total Annual Compensation, USD 889,651
Restricted Stock Award, USD 1,316,090
Long-Term Incentive Plans, USD --
All Other, USD 602,834
Fiscal Year Total, USD 2,808,570

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 189,929 2,785,120.00
Name Fiscal Year Total

Michael Mahoney

13,084,500

Daniel Brennan

3,632,770

Kevin Ballinger

2,808,570

Joseph Fitzgerald

5,839,000

Edward Mackey

3,818,020

Ian Meredith

--
As Of  31 Dec 2017